Heidi E. Kosiorek
YOU?
Author Swipe
View article: 444 Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancer
444 Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancer Open
View article: Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract Cancer
Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract Cancer Open
Molecular profiling reveals that up to 40% of advanced biliary tract cancers (BTCs) harbor actionable genomic alterations amenable to matched targeted therapies. However, conventional trial designs typically evaluate these agents in pretre…
View article: MPN Transformation Is Characterized By Heterogeneous Shifts In Lineage Character Resulting In Both HSC-Like And More Differentiated Lineage Signatures
MPN Transformation Is Characterized By Heterogeneous Shifts In Lineage Character Resulting In Both HSC-Like And More Differentiated Lineage Signatures Open
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have a propensity to transform to an accelerated or blast phase (MPN-AP/BP). The resulting disease has clinically similar manifestations to Acute Myeloid Leukemia (AML) b…
View article: External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy
External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy Open
Background Recently, a model to predict 5-year recurrence-free survival (RFS) and melanoma-specific survival (MSS) after sentinel lymph node biopsy (SLNB) was published. The aim of this study was to validate that model in a large independe…
View article: Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma
Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with Melanoma Open
View article: Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma
Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma Open
View article: Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Clinical info on the platelets-responsive and non-responsive patients
View article: Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
AVID200 induced similar decrements in the plasma levels of TGF-β in the three patients with and without platelet response
View article: Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Representativeness of Study Participants.
View article: Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Effects of AVID200 therapy on plasma TGFβ levels.
View article: Supplementary Figure S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
MPN-RC 118 phase 1b study schema
View article: Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Duration of treatment and response status.
View article: Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Baseline mutational profile of enrolled patients.
View article: Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Patient listing of prior myelofibrosis treatment and time since discontinuation if known
View article: Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
View article: Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S1 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Clinical info on the platelets-responsive and non-responsive patients
View article: Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Oncoprint Analysis of Serial Samples from Phase 1b Trial of AVID200
View article: Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Baseline mutational profile of enrolled patients.
View article: Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.
View article: Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Representativeness of Study Participants.
View article: Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (Lot A). Summary measures for DL 1 and DL2 are shown in red.
View article: Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Individual patient data for AUC, Cmax and Tmax for dose levels 1 and 2 (Lot A). Summary measures for DL 1 and DL2 are shown in red.
View article: Supplementary Figure S6 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S6 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
GATA1 expression in megakaryocytes from patients treated with AVID200
View article: Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Duration of treatment and response status.
View article: Data from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Data from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Purpose: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by systemic symptoms, cytopenias, organomegaly, and bone marrow fibrosis. JAK2 inhibitors afford symptom and spleen burden reduction but do not alter the dis…
View article: Supplementary Figure S5 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S5 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
The bone marrow from patients with MF contain more CD42pos cells than patients with ET or with hematopoietic malignancies without fibrosis (normal control).
View article: Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
AVID200 induced similar decrements in the plasma levels of TGF-β in the three patients with and without platelet response
View article: Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Effects of AVID200 therapy on plasma TGFβ levels.
View article: Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Oncoprint Analysis of Serial Samples from Phase 1b Trial of AVID200
View article: Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis
Supplementary Table S2 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis Open
Patient listing of prior myelofibrosis treatment and time since discontinuation if known